FDA proposes new registration rules for distributed drug manufacturing and foreign establishments
/ 1 min read
Table of Contents
The FDA is proposing changes to how drug manufacturers register their facilities and list their products. Currently, companies that manufacture drugs at several different physical locations often have to register each location separately. This proposal would create a way for a single company to register as one “distributed manufacturing establishment” even if its production happens across multiple sites.
Why it matters: This is primarily an administrative update designed to simplify registration for companies using multiple production sites and to bring existing agency rules in line with recent pandemic-related laws.
Who it affects
- Pharmaceutical companies that manufacture drugs at multiple different locations
This is a proposed rule from the Food and Drug Administration; readers should consult the Federal Register for full details before taking any action.
Agency: Health and Human Services Department, Food and Drug Administration
Source: Federal Register — read the official document